Abstract: Furthermore, L10 V/F/I (6.82%), A71V (4.55%), and I54V (4.55%) mutations were common in protease inhibitors (PIs).
Result: The PI mutations most commonly found were L10 V/F/I, A71V, and I54V, with DR rates of 6.82, 4.55, and 4.55%, respectively.
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Abstract: Common PI mutations were M46I, I54V, and V82A.
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.
Result: Of the 203 PI-associated SDRMs, the most common were L90M (33.5%), M46I/L (19.7%), I54V (10.8%), V82A/L/T (10.4%), and D30N plus N88D (9.8%).
The association between detected drug resistance mutations and CD4(+) T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
Abstract: Among individuals with at least one DRM, we found evidence that any nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, the reverse transcriptase (RT) mutations M184V, D67N and T215Y as well as the protease mutations V82A and I54V were associated with reduced CD4 declines.
HIV-1 transmission networks across Cyprus (2010-2012).
Result: The second study subject, also a Romanian citizen living in Cyprus, was also infected with a sub-subtype F1strain dual-class RT and PI resistant strain carrying D67N, K70R, M184V, T215F, Y181C, M46L, I54V and V82F mutations associated with drug resistance.
HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China.
Abstract: In addition, the protease inhibitor drug resistance mutations I54V and V82A were identified for the first time in Shandong Province.
Result: Additionally, the PIs drug resistance m
Discussion: Second, the I54V and V82A mutations about PIs discovered in the study were not found in patients on second line treatment, but found in two patients who remained on the first line treatment.
Discussion: The present study was the first to identify the PI-resistance mutations I54V and V82A in Shandong, and hence PIs should be carefully selected when we develop treatment regimens for these patients.
Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Abstract: Overall, 32% (37/116) patients presented >= one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and
Result: Only one patient (< 1%) was reported with major DRMs to protease inhibitors (PI/r), among which M46I, I54V, and V82S, indicating either an event of transmitted PI-associated DRMs or unknown past-exposure to PIs.
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
Discussion: Therefore, the curling conformation would also shield these residues, resulting in the inhibition of DRV binding to monomeric PR; in contrast, the presence of four mutations (V32I, L33F, I54V, and V82F) in FS5929R1 PR might directly impair the DRV binding to monomeric PR.
Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.
PMID: 27009474
2016
AIDS research and human retroviruses
Introduction: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M
Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Result: I54L (in PR20) and I54V (in PRS17) are major mutations associated with high-level resistance to most PIs, with the possible exception of DRV (for I54V).
Result: Mutations in PRS17 associated with resistance to multiple drugs are M46L, G48V, I54V, V82S and L90M.
Result: Of these, I54V and L90M are major drug resistance mutations.
Result: Only five of the mutations in PR22 are identical with those in PRS17, namely, <
HIV mutation literature information.
PMID: 
2019
Virology journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT